all report title image

Urea Cycle Disorder Treatment Market, By Treatment Type (Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, and Others (Low Protein Diet, Carglumic acid, etc.)), By Enzyme Deficiency Type (OTC – Ornithine Transcarbamylase, AS – Argininosuccinate Synthetase (citrullinemia), AG – Arginase, AL – Argininosuccinate Lyase, CPS1 – Carbamoyl Phosphate Synthase, and NAGS – N-acetylglutamate Synthase), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

  • Published In : Jul 2026
  • Code : CMI4441
  • Pages :258
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
  • 역사적 분포 범위 : 2020 - 2024
  • 기준 연도 : 2025
  • 예상 연도 : 2026
  • 예측 기간 : 2026 - 2033

The global urea cycle disorders treatment market includes various therapies such as amino acid supplements, sodium phenylbutyrate, glycerol phenylbutyrate, sodium benzoate, low protein diet, carglumic acid, etc. for the treatment of the inherited disorder such as urea cycle disorders, which affects various enzymes taking part in the urea cycle pathway in the human system. The urea cycle disorders are classified according to the deficiencies observed in different enzymes of the urea cycle such as OTC – ornithine transcarbamylase, ASD – argininosuccinic acid synthetase (citrullinemia), AG – Arginase, ALD – argininosuccinase acid lyase (argininosuccinic aciduria), CPS – carbamoyl phosphate synthetase, and NAGS – N-acetylglutamate synthetase.

Market Dynamics

Market players are focused on adopting different business strategies such as mergers and acquisitions in order to expand their offerings in the market.

For instance, in February 2017, Mead Johnson Nutrition Company (MJN) announced its merger with Reckitt Benckiser Group plc (RB).  Mead Johnson, now a division of RB, added its globally-recognized brands, including Enfa and Nutramigen, which are used in dietary management of urea cycle disorder, to RB’s consumer health portfolio, thus strengthening its position globally.

Moreover, For Instance, In October 2017, Lucane Pharma SA was acquired by the Eurocept Pharmaceuticals, a company developing, distributing, and marketing of medicinal products in therapeutic areas such as anesthesia, oncology, immunology, and neurology. This acquisition has aided Eurocept Pharmaceuticals to invest in research and development of medicines for rare metabolic diseases such as urea cycle disorders.

Furthermore, Key players focused on inorganic strategies such as distribution agreements in order to strengthen their presence in the market.

For Instance, In 2016, Horizon Pharma plc and Swedish Orphan Biovitrum AB (publ) (Sobi), a biotechnological company in Sweden, announced the distribution agreement for the distribution of Ravicti in European countries including the U.K,. Germany, Italy, France, and Spain.

Key features of the study

  • This report provides in-depth analysis of the global urea cycle disorders treatment market, provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2026–2033)
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
  • It profiles leading players in the global urea cycle disorders treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions with respect to their future market expansion and marketing tactics
  • The global urea cycle disorders treatment market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
  • Stakeholders would greatly benefit in decision-making through various strategy matrices used in analyzing the global urea cycle disorders treatment market

Market Segmentation

  • By Treatment Type (Revenue, USD Mn, 2021-2033)
    • Amino Acid Supplements
    • Sodium Phenylbutyrate
    • Glycerol Phenylbutyrate
    • Sodium Benzoate
    • Others (Low Protein Diet, Carglumic acid, etc.)
  • By Enzyme Deficiency Type (Revenue, USD Mn, 2021-2033)
    • OTC – Ornithine Transcarbamylase
    • AS – Argininosuccinate Synthetase (citrullinemia)
    • AG – Arginase
    • AL – Argininosuccinate Lyase
    • CPS1 – Carbamoyl Phosphate Synthase
    • NAGS – N-acetylglutamate Synthase
  • By Route of Administration (Revenue, USD Mn, 2021-2033)
    • Oral
    • Injectable
  • By Distribution Channel (Revenue, USD Mn, 2021-2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region (Revenue, USD Mn, 2021-2033)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Central Africa
      • North Africa
  • Key Players
    • Bausch Health Companies, Inc.
    • Recordati Rare Diseases Inc.
    • Lucane Pharma SA
    • Acer Therapeutics
    • Ultragenyx Pharmaceutical Inc.
    • Aeglea BioTherapeutics
    • Arcturus Therapeutics Holdings Inc.
    • Orpharma Pty Ltd.
    • Selecta Biosciences, Inc.
    • Abbott Laboratories
    • NESTLE S.A.
    • DANONE S.A.
    • Mead Johnson & Company, LLC

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Treatment Type
      • Market Snapshot, By Enzyme Deficiency Type
      • Market Snapshot, By Route of Administration
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Drivers
    • Restraints
    • Opportunities
    • Impact Analysis
    • Key Developments
    • Treatment Approaches
    • Novel Therapies Under Development for the Treatment of UCD
    • Mergers, Collaborations, Acquisitions & Agreements
    • Pipeline Analysis
    • Regulatory Scenario
    • PEST Analysis
    • Product Approvals
    • Market Trends
    • Epidemiology
    • Therapeutics Overview
    • Brand Analysis
    • Reimbursement Scenario
    • Prescription Overview
  4. Global Urea Cycle Disorders Treatment Market, By Treatment Type, 2021-2033 (USD Mn)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022-2033
      • Segment Trends
    • Amino Acid Supplements
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
    • Sodium Phenylbutyrate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
    • Glycerol Phenylbutyrate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
    • Sodium Benzoate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
    • Others (Low Protein Diet, Carglumic acid, etc.)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  5. Global Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type, 2021-2033 (USD Mn)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022-2033
      • Segment Trends
    • OTC – Ornithine Transcarbamylase
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
    • AS – Argininosuccinate Synthetase (citrullinemia)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
    • AG – Arginase
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
    • AL – Argininosuccinate Lyase
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
    • CPS1 – Carbamoyl Phosphate Synthase
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
    • NAGS – N-acetylglutamate Synthase
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  6. Global Urea Cycle Disorders Treatment Market, By Route of Administration, 2021-2033 (USD Mn)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022-2033
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
    • Injectable
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  7. Global Urea Cycle Disorders Treatment Market, By Distribution Channel, 2021-2033 (USD Mn)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022-2033
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
  8. Global Urea Cycle Disorders Treatment Market, By Region, 2021-2033 (USD Mn)
    • Introduction
      • Market Share Analysis, By Country, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, For Countries, 2022-2033
      • North America
    • Introduction
      • Market Size and Forecast, By Treatment Type, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Enzyme Deficiency Type, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Country, 2021-2033 (USD Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, By Treatment Type, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Enzyme Deficiency Type, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Country, 2021-2033 (USD Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, By Treatment Type, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Enzyme Deficiency Type, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Country, 2021-2033 (USD Mn)
        • Germany
        • U.K.
        • France       
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, By Treatment Type, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Enzyme Deficiency Type, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Country, 2021-2033 (USD Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, By Treatment Type, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Enzyme Deficiency Type, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Country, 2021-2033 (USD Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, By Treatment Type, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Enzyme Deficiency Type, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
      • Market Size and Forecast, By Country/Region, 2021-2033 (USD Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Company Profiles
      • Bausch Health Companies, Inc.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Recordati Rare Diseases Inc.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Lucane Pharma SA
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Acer Therapeutics
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Ultragenyx Pharmaceutical Inc.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Aeglea BioTherapeutics
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Arcturus Therapeutics Holdings Inc.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Orpharma Pty Ltd.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Selecta Biosciences, Inc.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Abbott Laboratories
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • NESTLE S.A.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • DANONE S.A.
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Mead Johnson & Company, LLC
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
  10. Section
    • References
    • Research Methodology
    • About Us
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2026 Coherent Market Insights Pvt Ltd. All Rights Reserved.